Precigen Inc (PGEN NASDAQ) stock market data APIs

$1.33 0.02(1.5%)
as of May 9, 2025
Try our APIs with free plan!

Precigen Inc Financial Data Overview

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Prev. Close 1.33
Open 1.3508
High 1.4242
Low 1.33
52 wk Range 0.6513-2.17
Market Cap 393 M
Shares Outstanding 295 M
Revenue 3 925 K
Beta 1.82

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Precigen Inc data using free add-ons & libraries


Get Precigen Inc Fundamental Data

Precigen Inc Fundamental data includes:

  • Net Revenue: 3 925 K
  • EBITDA: -90 179 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Precigen Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-05-12
  • EPS/Forecast: NaN
GET THE PACKAGE

Get Precigen Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Precigen Inc News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat